





---

Hier finden Sie eine Zusammenstellung der Veröffentlichungen von **Mitarbeiterinnen und Mitarbeitern** des BfArM aus dem Jahr 2021


## Originalarbeiten


Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, **Buchholz S**, Miller V, Hansen BE (2021) Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.  
*Clin Gastroenterol Hepatol* 19(3):463-472

Andlauer TFM, Guzman-Parra J, Streit F, Strohmaier J, Gonzalez MJ, Gil Flores S, Cabaleiro Fabeiro FJ, Del Rio Noriega F, Perez FP, Haro Gonzalez J, Orozco Diaz G, de Diego-Otero Y, Moreno-Küstner B, Auburger G, Degenhardt F, Heilmann-Heimbach S, Herms S, Hoffmann P, Frank J, Foo JC, Treutlein J, Witt SH, Cichon S, Kogevinas M, **Bipolar Disorder Working Group of the Psychiatric Genomics Consortium**, **Steffens M**, Major Depressive Disorder Working Group of the Psychiatric Genoms Consortium, Rivas F, Mayoral F, Müller-Myhsok B, Forstner AJ, Nöthen MM, Rietschel M (2019) Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders.  
*Mol Psychiatry* 26(4):1268-1298 

**Arshaad MI**, **Siwek M**, **Henseler C**, **Daubner J**, Ehninger D, Hescheler J, Sachinidis A, **Broich K**, **Papazoglou A**, **Weiergräber M** (2021) Enhanced hippocampal type II theta activity AND altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel.  
*Sci Rep* 11(1):1099 


Beck L, Witt R, Nesper-Brock M, Milde T, Hettmer S, Frühwald MC, Rössig C, Fischer M, Reinhardt D, Taylor LA, **Riedel C**, Witt O, van Tilburg CM (2021) A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development.  
*Clin Pharmacol Ther* 110(4):1025-1037 

Boeing C, Sandten C, Hrincius ER, Anhlan D, Dworog A, Hanning S, Kuennemann T, Niehues C, Schupp T, Stec E, Thume J, Triphaus D, Wilkens M, Uphoff H, **Zündorf J**, **Jacobshagen A**, Kreyenschmidt M, Ludwig S, Mertins HC, Mellmann A (2021) Decontamination of disposable respirators for reuse in a pandemic employing in-situ-generated peracetic acid.  
*Am J Infect Control* in press 

Correia Pinheiro L, Giezen TJ, Wolff-Holz E, **Weise M**, Laslop A, Hidalgo-Simon A (2021) Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.  
*Clin Pharmacol Ther* 110(5):1311-1317 




**Dubrall D\***, **Leitzen S\***, Toni I, Stingl J, Schulz M, Schmid M, Neubert A, **Sachs B** (2021) Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.

*BMC Pharmacol Toxicol* 22(1):56 

(\* geteilte Erstautorenschaft)


**Dubrall D**, Pflock R, Kosinska J, Schmid M, Bleich M, Himmerkus N, Offermanns S, Schwaninger M, **Sachs B** (2021) Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA2-mediated adverse reactions? A combined epidemiological-experimental approach.

*Br J Clin Pharmacol* 87(10):3813-3824 


Glitscher M, Martín DH, Woytinek K, Schmidt B, **Tabari D**, **Scholl C**, Stingl JC, Seelow E, Choi M, Hildt E (2021) Targeting cholesterol metabolism as efficient antiviral strategy against the Hepatitis E virus.

*Cell Mol Gastroenterol Hepatol* 12(1):159-180 

Gomm W, Röthlein C, Schüssel K, Brückner G, Schröder H, **Hess S**, **Frötschl R**, **Broich K**, **Haenisch B** (2021) N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer – A Longitudinal Cohort Study Based on German Health Insurance Data.

*Dtsch Arztebl Int* 118(21):357-362 


**Haas B**, **Ciftcioglu J**, **Jermar S**, **Weickhardt S**, **Eckstein N**, Kaina B (2021) Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.

*J Cancer Res Clin Oncol* 147(3):779-792 


Herrlein ML, Schmanke P, Elgner F, Sabino C, Akhras S, Bender D, Glitscher M, **Tabari D**, **Scholl C**, Stingl J, Hildt E (2021) Catch me if you can - the crosstalk of ZIKV and the restriction factor Tetherin.

*J Virol* Online ahead of print 

Huber C, **Benda N**, Friede T (2021) Subgroup identification in individual participant data meta-analysis using model-based recursive partitioning.

*Adv Data Anal Classi* 

**Huber C**, Friede T, Stingl J, **Benda N** (2021) Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection.


*Ther Innov Regul Sci* Online ahead of print 




Just KS, Dallmeier D, **Böhme M, Steffens M**, Braisch U, Denkinger MD, Rothenbacher D, Stingl JC, ActiFE Study Group (2021) Fall-Associated Drugs in Community-Dwelling Older Adults: Results from the ActiFE Ulm Study.

*J Am Med Dir Assoc* 22(10):2177-2183


Just KS, Dormann H, Freitag M, **Schurig MA, Böhme M, Steffens M, Scholl C**, Seufferlein T, Gräff I, Schwab M, Stingl JC (2021) CYP2D6 in the brain: potential impact on adverse drug reactions in the central nervous system - Results from the ADRED study.

*Front Pharmacol* 12:624104 


**Just KS, Scholl C, Böhme M**, Kastenmüller K, Just JM, Bleckwenn M, Holdenrieder S, Meier F, Weckbecker K, Stingl JC (2021) Individualized Versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial) – Never Change a Running System?

*Pharmaceuticals* 14(10):1056 

**Kemski S, Molitor V, Steffens M**, Nümm T, Herrmann N, Hornung T, Bieber T, Schumann C, Kächele V, Seufferlein T, Heinemann V, **Scholl C**, Stingl JC (2021) Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity.

*Oncotarget* 12(10):982-995 


**Leitzen S, Dubrall D**, Toni I, Stingl J, Schulz M, Schmid M, Neubert A, **Sachs B** (2021) Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019.

*PLoS One* 16(3):e0247446 


**Leitzen S, Kayser C, Weißmann K, Sachs B** (2021) Arzneimittelnebenwirkungen und Medikationsfehler bei Kindern.

*Monatsschr Kinderheilkd* Online ahead of print 

**Leitzen S, Vogel M, Engels A, Zapf T**, Brandl M (2021) Identification and quantification of glucose degradation products in heat-sterilized glucose solutions for parenteral use by thin-layer chromatography.

*PLoS One* 16(7): e0253811 

**Leitzen S, Vogel M, Steffens M, Zapf T**, Müller CE, Brandl M (2021) Quantification of Degradation Products Formed during Heat Sterilization of Glucose Solutions by LC-MS/MS: Impact of Autoclaving Temperature and Duration on Degradation.

*Pharmaceuticals* 14(11):1121 



Mufwambi W, Stingl J, Masimirembwa C, Manasa J, Nhachi C, **Stadler N**, Mwila C, Kalungia AC, Mukosha M, Mutiti CS, Kamoto A, Kaonga P, Godman B, Munkombwe D (2021) Healthcare Professionals' Knowledge of Pharmacogenetics and Attitudes Towards Antimicrobial Utilization in Zambia: Implications for a Precision Medicine Approach to Reducing Antimicrobial Resistance. *Front Pharmacol* 11(2183) [OPEN ACCESS](#)

Mutiti CS, Kapungu NN, Kanji CR, **Stadler N**, Stingl J, Nhachi C, Hakim J, Masimirembwa C, Thelingwani RS (2021) Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir. *Pharmacol Res Perspect* 9(3):e00769, doi: 10.1002/prp2.769 [OPEN ACCESS](#)

**Papazoglou A, Arshaad MI, Siwek ME, Henseler C, Daubner J**, Ehninger D, Hescheler J, **Broich K, Weiergräber M** (2021) Spontaneous long-term and urethane induced hippocampal EEG power, activity and temperature data from mice lacking the Ca<sub>v</sub>3.2 voltage-gated Ca<sup>2+</sup> channel. *Data in Brief* 36:107027 [OPEN ACCESS](#)

**Papazoglou A, Henseler C, Broich K, Daubner J, Weiergräber M** (2021) Breeding of Ca<sub>v</sub>2.3 deficient mice reveals Mendelian inheritance in contrast to complex inheritance in Ca<sub>v</sub>3.2 null mutant breeding. *Sci Rep* 11(1):13972 [OPEN ACCESS](#)

**Schmidt-Wolf G, Cremer-Schaeffer P** (2021) 3 Jahre Cannabis als Medizin - Zwischenergebnisse der Cannabisbegleiterhebung. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64(3):368-377 [OPEN ACCESS](#)

**Schmidt-Wolf G, Cremer-Schaeffer P** (2021) Interim Results of the Survey Accompanying the Prescription of Cannabis-Based Medicines in Germany Regarding Dronabinol [Kurzbeitrag]. *Dtsch Arztebl Int* 118(10):177-178 [OPEN ACCESS](#)

Siener R, Seidler A, **Hönow R** (2021) Oxalate-rich foods. *Food Sci Technol* 41 (Suppl 1):169-173 [OPEN ACCESS](#)

Stingl JC, **Scholl C**, Bosch JE, Viviani R (2021) Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain. *Transl Psychiatry* 11(1):467 [OPEN ACCESS](#)

Vergallo A, Lista S, Zhao Y, Lemercier P, Teipel SJ, Potier MC, Habert MO, Dubois B, Lukiw WJ, Hampel H (2021) for the INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI) (**Benda N, Broich K, Haberkamp M, Haenisch B**): MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. *Transl Psychiatry* 11(1):78 [OPEN ACCESS](#)




**Yamoune S**, Wintz K, Niederau C, Craveiro RB, Wolf M, Stingl J (2021) Role of cytochrome P450 2C8 genetic polymorphism and epoxygenase uncoupling in periodontal remodelling affecting orthodontic treatment.

*Basic Clin Pharmacol Toxicol* Online ahead of print 

## Reviews


Araujo-Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, **Enzmann H**, Pignatti F (2021) The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.

*ESMO Open* 6(1):100008 


Babiloni C, Arakaki X, Azami H, Bennys K, Blinowska K, Bonanni L, Bujan A, Carrillo MC, Cichocki A, de Frutos-Lucas J, Del Percio C, Dubois B, Edelmayer R, Egan G, Epelbaum S, Escudero J, Evans A, Farina F, Fargo K, Fernández A, Ferri R, Frisoni G, Hampel H, Harrington MG, Jelic V, Jeong J, Jiang Y, Kaminski M, Kavcic V, Kilborn K, Kumar S, Lam A, Lim L, Lizio R, Lopez D, Lopez S, Lucey B, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Noce G, Olichney J, Onofrij M, Osorio R, Parra-Rodriguez M, Rajji T, Ritter P, Soricelli A, Stocchi F, Tarnanas I, Taylor JP, Teipel S, Tucci F, Valdes-Sosa M, Valdes-Sosa P, **Weiergräber M**, Yener G, Guntekin B (2021) Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.

*Alzheimers Dement* 17(9):1528-1553


Blume H, Mehta M, Beuerle G, Dorantes A, Hempel G, Jiang W, Kovar A, Lee J, **Potthast H**, Schug B, Seidlitz A, Tampal N, Tsang Y, Walstab J, Welink J (2021) The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference.

*Eur J Pharm Sci* 167:105987 

**Broich K, Löbker W, Lauer W** (2021) Beitrag des BfArM zur Potenzialentfaltung der Digitalisierung im Gesundheitswesen - digital readiness@BfArM.

*Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64(10):1292-1297 


Chorley BN, Atabakhsh E, Doran G, Gautier JC, Ellinger-Ziegelbauer H, Jackson D, Sharapova T, Yuen PST, Church RJ, Couttet P, **Frötschl R**, McDuffie J, Martinez V, Pande P, Peel L, Rafferty C, Simutis FJ, Harrill AH (2021) Methodological considerations for measuring biofluid-based microRNA biomarkers.


*Crit Rev Toxicol* 51(3):264-282 





**Cremer-Schaeffer P** (2021) Cannabis als Medizin: Sonderregelungen sicher anwenden.


*Anesthesiol Intensivmed Notfallmed Schmerzther* 56(4):297-302


**Daubner J, Arshaad MI, Henseler C, Hescheler J, Ehninger D, Broich K, Rawashdeh O, Papazoglou A, Weiergräber M** (2021) Pharmacological Neuroenhancement - Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics and Future Perspectives. *Neural Plast* 2021(8823383) , <https://doi.org/10.1155/2021/8823383>


Delgado J, Josephson F, Camarero J, Garcia-Ochoa B, Lopez-Anglada L, Prieto-Fernandez C, van Hennik PB, Papadouli I, Gisselbrecht C, **Enzmann H**, Pignatti F (2021) EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. *Oncologist* 26(3):242-249 

Delgado J, Papadouli I, Sarac SB, Moreau A, Hovgaard D, Gisselbrecht C, **Enzmann H**, Pignatti F (2021) The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. *Hemasphere* 5(12):e666 

Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, **Enzmann H**, Pignatti F (2021) The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. *ESMO Open* 6(2):100087 


Delgado J, Vleminckx C, Sarac S, Sosa A, Bergh J, Giuliani R, **Enzmann H**, Pignatti F (2021) The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. *ESMO Open* 6(2):100074 

Delgado J, Voltz C, Stain M, Balkowiec-Iskra E, Mueller B, Wernsperger J, Malinowska I, Gisselbrecht C, **Enzmann H**, Pignatti F (2021) The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. *Hemasphere* 5(8):e616 

Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähtenvuo J, Penttilä K, Gisselbrecht C, **Enzmann H**, Pignatti F (2021) The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease. *Hemasphere* 5(7):e604 




Delgado J, Zienowicz M, van Hennik PB, Moreau A, Gisselbrecht C, **Enzmann H**, Pignatti F (2021) EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

*Oncologist* 26(11):983-987 

Drösler SE, **Weber S**, Chute CG (2021) ICD-11 extension codes support detailed clinical abstraction and comprehensive classification.

*BMC Med Inform Decis Mak* 21(Suppl 6):278 


Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, **Greiner C**, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C (2021) Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.

*World J Biol Psychiatry* 22(8):561-628 


Eggers M, **Baumann A**, **Lilienthal N**, Steinmann E, Steinmann J, Hübner NO, Rabenau HF, Weinheimer V, Schwebke I (2021) Desinfektionsmittel in der COVID-19-Pandemie: eine Herausforderung.

*Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* Online ahead of print 

Elliott P, Cowie MR, Franke J, Ziegler A, Antoniadis C, Bax J, Bucciarelli-Ducci C, Flachskampf FA, Hamm C, Jensen MT, Katus H, Maisel A, McDonagh T, **Mittmann C**, Muntendam P, Nagel E, Rosano G, Twerenbold R, Zannad F (2021) Development, validation and implementation of biomarker testing in cardiovascular medicine state-of-the-art: Proceedings of the European Society of Cardiology - Cardiovascular Round Table.

*Cardiovasc Res* 117(5):1248-1256 

Fatangare A, **Glässner A**, **Sachs B**, Sickmann A (2021) Future perspectives on *in-vitro* diagnosis of drug allergy by the lymphocyte transformation test.


*J Immunol Methods* 495:113072 

**Fürst-Wilmes M**, **Respondek V**, **Lilienthal N**, **Brake B**, **Düchting A** (2021) Bakteriophagen als Arzneimittel – eine regulatorische Perspektive.

*Pharmakon* 9(6):461-468



Garcia Arieta A, Simon C, Tam A, Mendes Lima Santos G, Freitas Fernandes EA, Rodríguez Martínez Z, Rodrigues C, Park SA, Kim J, Kim K, Kuribayashi R, Myoenzono A, Shimojo K, Walther C, Roost MS, Hung WY, Hsu LF, Crane C, Braddy AC, Van Oudtshoorn J, Gutierrez Triana DA, Guzmán Aurela E, Jones B, **Potthast H**, Abalos I (2021) A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme.

*J Pharm Pharm Sci* 24:113-126 


Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, **Haenisch B, Haberkamp M, Broich K**, Nistico R, Emanuele E, Llaveró F, Zugaza J, Lucia A, Giacobini E, Lista S (2021) for the Alzheimer Precision Medicine Initiative: Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

*Neuropharmacology* 185:108081


Harrison JE, **Weber S**, Jakob R, Chute CG (2021) ICD-11: an international classification of diseases for the twenty-first century.

*BMC Med Inform Decis Mak* 21(Suppl 6):206 


**Hübner T, Scholl C, Steffens M** (2021) Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe.

*Diagnostics* 11(7):1169 

**Hübner T, Steffens M, Scholl C** (2021) Molecular Genetic Techniques in Biomarker Analysis Relevant for Drugs Centrally Approved in Europe.

*Mol Diagn Ther* Online ahead of print 


**Lauer W, Löbker W, Höfgen B** (2021) Digitale Gesundheitsanwendungen (DiGA): Bewertung der Erstattungsfähigkeit mittels DiGA-Fast-Track-Verfahrens im Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).

*Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64(10):1232-1240 

**Lilienthal N, Baumann A, Respondek V**, Hübner NO, Schwebke I (2021) Quo vadis Händedesinfektionsmittel: Arzneimittel oder Biozidprodukt?

*Epid Bull* 17:5-13

**Löbker W, Böhmer A, Höfgen B** (2021) Innovationsunterstützung im BfArM - Erfahrungen aus den Beratungen zu digitalen Gesundheitsanwendungen (DiGA).


*Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64(10):1241-1248 






---


Nicolette J, Luijten M, Sasaki JC, Custer L, Embry M, **Frötschl R**, Johnson G, Ouedraogo G, Settivari R, Thybaud V, Dearfield KL (2021) Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.

*Environ Mol Mutagen* 62(9):512-525 


**Papazoglou A, Arshaad MI, Henseler C, Daubner J, Broich K, Haenisch B, Weiergräber M** (2021) The Janus-like Association Between Proton Pump Inhibitors and Dementia.

*Curr Alzheimer Res* 18(6):453-469 


Roost MS, **Potthast H**, Walther C, García-Arieta A, Abalos I, Agostinho Freitas Fernandes E, Mendes Lima Santos G, Rodríguez Martínez Z, Tam A, Rodrigues C, Gutierrez Triana DA, Guzmán Aurela E, Rodríguez Rodríguez N, Aeh Park S, Kim J, Kariv R, Divinsky M, Jones B, Kuribayashi R, Myoenzono A, Kasuga M, Van Oudtshoorn J, Chi JF, Hung WY, Hsu LF, Crane C, Jarman T, Braddy A (2021) Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities.

*J Pharm Pharm Sci* 24:548-562 


Ruepp R, **Frötschl R**, Bream R, Filancia M, Girard T, Spinei A, **Weise M**, Whomsley R (2021) The EU Response to the Presence of Nitrosamine Impurities in Medicines.

*Front Med* 8:782536 


**Sachs B**, Fatangare A, Sickmann A, **Glässner A** (2021) Lymphocyte transformation test: History and current approaches.

*J Immunol Methods* 493:113036 

Schrenk D, Fahrer J, Allemang A, Fu P, Lin G, Mahony C, Mulder PPJ, Peijnenburg A, Pfuhler S, Rietjens I, Sachse B, Steinhoff B, These A, Troutman J, **Wiesner J** (2021) Novel Insights into Pyrrolizidine Alkaloid Toxicity and Implications for Risk Assessment: Occurrence, Genotoxicity, Toxicokinetics, Risk Assessment-A Workshop Report.


*Planta Med* Online ahead of print 

Semete-Makokotlela B, Mahlangu GN, Mukanga D, Darko DM, Stonier P, Gwaza L, Nkambule P, Matsoso P, **Lehnert R**, Rosenkranz B, Pillai GC (2021) Needs-driven talent and competency development for the next generation of regulatory scientists in Africa.


*Br J Clin Pharmacol* Online ahead of print 




Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx B, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, **Aislaitner G**, Butlen-Ducuing F, Fletcher C, **Haberkamp M**, Laughren T, Mäntylä FL, Schruers K, Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM (2021) A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.

*Mol Psychiatry* Online ahead of print 


Sheean ME, **Naumann-Winter F**, Capovilla G, Kalland ME, Malikova E, Mariz S, Matusevicius D, Nistico R, Schwarzer-Daum B, Tsigkos S, Tzogani K, Larsson K, Magrelli A, Stoyanova-Beninska V (2021) Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective.

*Front Med* 8:744625 

Trullas A, Delgado J, **König J**, **Fürstenau U**, **Dedorath J**, **Hausmann S**, **Stock T**, **Enzmann H**, Pignatti F (2021) The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.

*ESMO Open* 6(1):100031 

**Weber S**, Heitmann KU (2021) Interoperabilität im Gesundheitswesen: auch für digitale Gesundheitsanwendungen (DiGA) verordnet.


*Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64(10):1262-1268 

**Wiesner J** (2021) Regulatory Perspectives of Pyrrolizidine Alkaloid Contamination in Herbal Medicinal Products.

*Planta Med* doi: 10.1055/a-1494-1363. Online ahead of print

## Sonstige Publikationen

Arlett P, Kjaer J, **Broich K**, Cooke E (2021) Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value.

*Clin Pharmacol Ther* Online ahead of print 




**Blumberg A, Chatterjee S, Kommas E, Huber M** (2021) Aktuelles aus dem BfArM – die Sondersitzung 2021 des Sachverständigen-Ausschusses (SVA) für Verschreibungspflicht. *Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 3:18-25


**Blumberg A, Chatterjee S, Kommas E, Huber M** (2021) Antihistaminika der ersten Generation – Risikoaspekte bei älteren Menschen und Diskussion zur Verkaufsabgrenzung. *Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 1:4-10

**Broich K** (2021) Digitale Gesundheitsanwendungen in der Versorgung: Von der Idee zum Patienten.


*iX-Forum - Gesundheitspolitik in der Diskussion* Ausgabe 1:10-12 

**Broich K, Löbker W, Weber S** (2021) Digitale Gesundheitsdaten: Standardisierung und Nutzbarmachung. *Schriftenreihe Interdisziplinäre Plattform zur Nutzenbewertung – Digitale Gesundheitsdaten: Nutzen, Kosten, Governance* 12:32-41 

Cavaleri M, **Enzmann H**, Straus S, Cooke E (2021) The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines [comment].


*Lancet* 397(10272):355-357 

**Dubrall D**, Pflock R, Kosinska J, Schmid M, Bleich M, Himmerkus N, Offermanns S, Schwaninger M, **Sachs B** (2021) Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA2-mediated adverse reactions? A combined epidemiological-experimental approach [Meeting Abstract].

*Naunyn Schmiedebergs Arch Pharmacol* 394(SUPPL 1):S11, Meeting Abstract 33 

**Dubrall D**, Schulz M, Schmid M, **Sachs B** (2021) Beta-lactam-associated hypersensitivity reactions: descriptive analysis of adverse drug reaction reports from Germany [Meeting Abstract V17]. *Allergologie* 44(2):159-160

Guth S, Hüser S, Roth A, Degen G, Diel P, Edlund K, Eisenbrand G, Engel KH, Epe B, Grune T, Heinz V, Henle T, Humpf HU, Jäger H, Joost HG, Kulling SE, Lampen A, Mally A, Marchan R, Marko D, Mühle E, Nitsche MA, **Röhrdanz E**, Stadler R, van Thriel C, Vieths S, Vogel RF, Wascher E, Watzl C, Nöthlings U, Hengstler JG (2021) Contribution to the ongoing discussion on fluoride toxicity [Reply].


*Arch Toxicol* 95(7):2571-2587 

**Habijan J** (2021) Sind Explantationen von Medizinprodukten immer schwerwiegende Vorkommnisse? - Risikobewertung, Fehlerursachen und Meldepflichten im Lichte der "neuen" Verordnung (EU) 2017/45 (MDR). *Concept Ophthalmologie* 6/2021




**Knöss W, Heldt C, Ledderhose C, Otting H, Retterath R** (2021) Cannabis for medical use - implementation of a new regulation in Germany [Kongressbeitrag].  
*Planta Med* 87:1283


**Lamkemeyer T, Sachs B, Lütkehermölle W** (2021) Gadoliniumhaltige Kontrastmittel: Ablagerungen im Körper und Gehirn und möglicherweise damit im Zusammenhang stehende langfristige Folgewirkungen – aktueller Stand und Ausblick aus regulatorischer Sicht.  
*Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 2:4-12

**Lauer W, Löbker W, Sudhop T, Broich K** (2021) Digitale Gesundheitsanwendungen (DiGA) als innovativer Baustein in der digitalen Gesundheitsversorgung in Deutschland – Informationen, Erfahrungen und Perspektiven [Editorial].  
*Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64(10):1195-1197 

**Löbker W, Broich K** (2021) Die App auf Rezept: Das Fast-Track-Verfahren. Berlin-Brandenburgische Akademie der Wissenschaften (BBAW).  
*Schriftenreihe Denkanstöße* Februar 2021

Mbichila T, Kumwenda G, Yola N, Karim QA, Tchelidze T, Lau J, **Buchholz S, Lehnert R**, Molina JM, Mayer K, Miller V (2021) Commentary title: COVID-19 research, Africa, and global health.  
*J Virus Erad* 7(1):100030 


**Meier T, Seemann W** (2021) Natrium-Glukose-Co-Transporter-2-Hemmer (SGLT2-Inhibitoren) und das Auftreten von diabetischer Ketoazidose (DKA).  
*Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 4:4-14


Moissl A, Dawczynski C, Delgado G, Kleber ME, Maerz W, Kramer B, Pilz S, Scharnagl H, **Siekmeier R**, Silbernagel G, Tomaschitz A, Winkelhofer-Roob B, Lorkowski S (2021) Carotenoids, Vitamin A and mortality: The Ludwigshafen Risk and Cardiovascular Health (-LURIC) study (52. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin).  
*Wien Klin Wochenschr* 133(Suppl 5):188-189, Meeting Abstract P25 

**Ortiz de Orue Lucana D, Seemann W, Eucker T, Grüger T** (2021) Fluorchinolone und ihr Risiko für Herzklappenregurgitation/-insuffizienz – neuer Warnhinweis in den Produktinformationen.  
*Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 1:11-19

Parrau N, Said A, Ganso M, Schulz M, **Kayser C** (2021) Dosierung flüssiger Zubereitungen zum Einnehmen – Potenzial für Medikationsfehler.  
*Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 2:25-35



**Sachs B, Glässner A** (2021) Editorial - Special Issue on in vitro detection of drug allergy [Editorial].  
*J Immunol Methods*:113004 

Seifried J, Böttcher S, von Kleist M, Jenny M, Antao E, Oh D, Jung-Sendzik T, **Broich K**, Denkinger C, Bartenschlager T, Schaade L, Hamouda O, Mielke M (2021) Antigentests als ergänzendes Instrument in der Pandemiebekämpfung.  
*Epid Bull* 17:14-25 

**Stephan K, Sherwood K, Teklenburg-Todt P** (2021) Pharmakovigilanz-Inspektionen und Besonderheiten in Zeiten der Pandemie.  
*Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 3:10-17

**Vogel M** (2021) Weiterentwicklung und Einsatz massenspektrometrisch basierter Screeningverfahren zum Nachweis toxikologisch bedenklicher N-Nitrosamine in Arzneimitteln.  
*Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI* 4:25-30

## **Bücher/Buchbeiträge**

**Broich K** (2021) Sieben aktuelle Thesen des BfArM nach dem ersten DiGA-Jahr. In: McKinsey & Company, Richter L, Silberzahn T (Hrsg) eHealth Monitor 2021 - Deutschlands Weg in die digitale Gesundheitsversorgung - Status Quo und Perspektiven. MWV Medizinisch Wissenschaftliche Verlagsgesellschaft mbH & Co. KG, S. 133-137

Kaina B, Thomas A, Visser H, Hengstler J, **Frötschl R** (2021) Do Carcinogens Have a Threshold Dose? The Pros and Cons. In: Reichl FX, Schwenk M (Hrsg) Regulatory Toxicology. Springer, Berlin, Heidelberg, 1-19

**Kirch K, Weber S** (2021) Codierung von seltenen Erkrankungen. In: Mücke M, Conrad C (Hrsg) ELSEVIER ESSENTIALS, Seltene Erkrankungen - Das Wichtigste für Ärztinnen und Ärzte aller Fachrichtungen. Elsevier GmbH, Deutschland, 107-110

**Löbker W, Broich K** (2021) Der DiGA Fast-Track für die "App auf Rezept" - Bisherige Erfahrungen aus Sicht des BfArM. In: Jorzig A, Matusiewicz D (Hrsg) Digitale Gesundheitsanwendungen (DiGA) - Rechtliche Grundlagen, innovative Technologien und smarte Köpfe - Gesundheitswesen in der Praxis. medhochzwei, S. 111-124

Möller H, **Broich K** (2021) Methodik klinischer psychopharmakologischer Therapieforschung. In: Laux G, Müller WE (Hrsg) Psychopharmakologie und Psychopharmakotherapie kompakt - Weiterbildungs-Curriculum zum Facharzt für Psychiatrie und Psychotherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart

**Röhrdanz E, Eucker T, Herrington C, Höschele D, Kudicke S** (2021) Wie werden Arzneimittel auf die Sicherheit ihrer Anwendung in der Schwangerschaft überprüft? In: BARMER (Hrsg) Barmer Arzneimittelreport 2021 - Arzneimitteltherapie in der Schwangerschaft und bei Frauen im gebärfähigen Alter, S. 172-181